Micko
Thats correct.
My take is that because the company has now started the TRIPP study, and the percutaneous study, which are company funded, clinicians will try to put the patient’s treatments through the trials rather than self fund or hospital funded.
The German trial would be different because the health funds will pay for the Oncosil treatments in that one.
While that means fewer sales it will speed up the trial enrolment. Also improves clinician engagement with the company.
Agree re UK. No idea why they haven’t been able to get sales there.
MickoThats correct. My take is that because the company has now...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.03 |
Change
0.015(1.48%) |
Mkt cap ! $14.65M | |||
| Open | High | Low | Value | Volume |
| $1.05 | $1.05 | 95.0¢ | $109.7K | 112.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 23906 | $1.00 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.05 | 2292 | 2 |
View Market Depth
| Last trade - 15.57pm 19/06/2025 (20 minute delay) ? |
| OSL (ASX) Chart |